Skip to content
Menu

Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.

Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.

Read at benzinga.com

← All stock news